Connection

THOMAS MONATH to Dengue Virus

This is a "connection" page, showing publications THOMAS MONATH has written about Dengue Virus.
Connection Strength

2.165
  1. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol. 2009 Jul; 16(7):1052-9.
    View in: PubMed
    Score: 0.297
  2. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
    View in: PubMed
    Score: 0.214
  3. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004 May; 78(9):4761-75.
    View in: PubMed
    Score: 0.209
  4. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002 Jun 20; 298(1):146-59.
    View in: PubMed
    Score: 0.184
  5. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001 Aug; 75(16):7290-304.
    View in: PubMed
    Score: 0.173
  6. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000 Jun; 74(12):5477-85.
    View in: PubMed
    Score: 0.159
  7. Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol. 2013 Oct; 19:292-311.
    View in: PubMed
    Score: 0.097
  8. Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med. 2007 Nov 29; 357(22):2222-5.
    View in: PubMed
    Score: 0.067
  9. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg. 2006 Nov; 75(5):986-93.
    View in: PubMed
    Score: 0.062
  10. Geographic classification of dengue-2 virus strains by antigen signature analysis. Virology. 1986 Oct 30; 154(2):313-24.
    View in: PubMed
    Score: 0.062
  11. Multisite monoclonal immunoassay for dengue viruses: detection of viraemic human sera and interference by heterologous antibody. J Gen Virol. 1986 Apr; 67 ( Pt 4):639-50.
    View in: PubMed
    Score: 0.060
  12. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
    View in: PubMed
    Score: 0.059
  13. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg. 2005 Jan; 72(1):74-81.
    View in: PubMed
    Score: 0.055
  14. High fidelity of yellow fever virus RNA polymerase. J Virol. 2004 Jan; 78(2):1032-8.
    View in: PubMed
    Score: 0.051
  15. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg. 2004 Jan; 70(1):89-97.
    View in: PubMed
    Score: 0.051
  16. Genetic variation among dengue 2 viruses of different geographic origin. Virology. 1983 Jul 30; 128(2):271-84.
    View in: PubMed
    Score: 0.050
  17. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res. 2003; 61:469-509.
    View in: PubMed
    Score: 0.048
  18. Fluorescent antibody techniques applied to the identification of dengue virus in infected tissue. Acta Virol. 1982 Sep; 26(5):376-81.
    View in: PubMed
    Score: 0.047
  19. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg. 2002 Sep; 67(3):260-5.
    View in: PubMed
    Score: 0.047
  20. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine. 1997 Oct; 15(14):1494-502.
    View in: PubMed
    Score: 0.033
  21. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis. 2017 03; 17(3):e101-e106.
    View in: PubMed
    Score: 0.031
  22. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A. 1994 Mar 29; 91(7):2395-400.
    View in: PubMed
    Score: 0.026
  23. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010 Jan 08; 28(3):632-49.
    View in: PubMed
    Score: 0.019
  24. Genetic variation and microevolution of dengue 2 virus in Southeast Asia. Virology. 1989 Oct; 172(2):523-35.
    View in: PubMed
    Score: 0.019
  25. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol. 1988 Aug; 69 ( Pt 8):1921-9.
    View in: PubMed
    Score: 0.018
  26. Genetic and epidemiological studies of dengue type 2 viruses by hybridization using synthetic deoxyoligonucleotides as probes. J Gen Virol. 1986 Dec; 67 ( Pt 12):2645-61.
    View in: PubMed
    Score: 0.016
  27. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. Trans R Soc Trop Med Hyg. 1977; 71(1):60-5.
    View in: PubMed
    Score: 0.008
  28. Comparison of methods for removal of nonspecific inhibitors of arbovirus hemagglutination. Appl Microbiol. 1970 Nov; 20(5):748-53.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.